Skip to content

US · FENC · BIOTECHNOLOGY

Fennec Pharmaceuticals Inc. (FENC) intrinsic value and stock valuation

$13.09as of 2026-11-21 · Mkt cap 365.43M

Data updated · price as of 2026-11-21

Strongly undervaluedIC value is more than 50% above the price. The exact IC value, upside and the fair-value band are available with Pro.
P/E
Pro
P/B
Pro
P/S
Pro

Price history

Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.

Fennec Pharmaceuticals Inc. DCF and intrinsic value

InvestorsCraft values FENC with the Chepakovich two-stage DCF model — currently rated strongly undervalued. How the model works · Run your own DCF prefilled from FENC’s statements →

Fennec Pharmaceuticals Inc. Graham Number

The Graham Number is not defined for negative earnings or book value. Guide · Calculator →

Healthcare · Biotechnology Research Triangle Park, NC 27709 fennecpharma.com

How the business is doing

Fiscal 2011–2025, USD

Revenue
$44.6M+204.7% 5y CAGRd
20112025
Net income
-$-9.74M
20112025
Free cash flow
-$-12.47M
20112025
Total equity
$35.1M+3.8% 5y CAGRd
20112025

Is it expensive?

Each multiple against its own 15-year range, or against peers where no history is available

P/E
Pro
with Pro
P/B
Pro
with Pro
P/S
Pro
with Pro
EV/EBITDA
Pro
with Pro
P/EG
Pro
with Pro
P/TBV
Pro
with Pro

Peers

Same-industry companies, ranked by market cap

Peer comparison

The peer comparison table is shown only to users with a Pro subscription.

Financials

Statements by fiscal year

Fiscal 2011–2025, USD
20252024202320222021
Revenue$44.6M$47.5M$21.3M$1.53M$0.00
Operating income-$-6.35M$2.48M-$-13.06M-$-22.74M-$-17.22M
Net income-$-9.74M-$-440K-$-16.05M-$-23.71M-$-17.35M
EPSd-$-340.8K-$-16.12K-$-604.06K-$-902.55K-$-667.05K
Operating cash flow-$-12.47M$27M-$-17.14M-$-18.06M-$-14.22M
Capital expenditure$0.00$0.00$0.00$0.00$0.00
Free cash flow-$-12.47M$27M-$-17.14M-$-18.06M-$-14.22M
Total assets$70.1M$45M$26.9M$26.9M$22.4M
Total debt$0.00$19.3M$31M$24.9M$4.99M
Net debt-$-36.72M-$-7.29M$17.7M$1.12M-$-16.11M
Total equity$35.1M-$-5.87M-$-11.62M-$-2.57M$15.8M
Cash and short-term investments$36.7M$26.6M$13.3M$23.8M$21.1M
Income statement
20252024202320222021
Revenue$44.6M$47.5M$21.3M$1.53M$0.00
Cost of revenue$3.76M$3.18M$1.26M$90K$0.00
Gross profit$40.9M$44.4M$20M$1.45M$0.00
Research and development expenses$250K$310K$60K$3.53M$4.98M
Selling, general and administrative expenses$46.9M$41.5M$32.7M$20.5M$12.2M
Other expenses$60K$90K$290K$150K$0.00
Operating expenses$47.2M$41.9M$33.1M$24.2M$17.2M
Cost and expenses$51M$45.1M$34.3M$24.3M$17.2M
Interest income$790K$1.59M$440K$200K$50K
Interest expense$2.08M$4.07M$3.39M$980K$130K
Depreciation and amortization$100K$800K$290K$150K$20K
Ebitda-$-7.45M$4.8M-$-12.36M-$-22.59M-$-17.22M
Operating income-$-6.35M$2.48M-$-13.06M-$-22.74M-$-17.22M
Total other income/expenses, net-$-3.29M-$-2.55M-$-2.99M-$-980K-$-120K
Income before tax-$-9.63M-$-70K-$-16.05M-$-23.71M-$-17.35M
Income tax expense$110K$360K$0.00$0.00$0.00
Net income-$-9.74M-$-440K-$-16.05M-$-23.71M-$-17.35M
Weighted average shares outstanding$28.6M$27.3M$26.6M$26.3M$26M
Weighted average diluted shares outstanding$28.6M$27.3M$26.6M$26.3M$26M
Balance sheet
20252024202320222021
Cash and short-term investments$36.7M$26.6M$13.3M$23.8M$21.1M
Net receivables$23.2M$12.9M$8.81M$1.54M$0.00
Inventory$1.56M$1.06M$2.16M$580K$0.00
Total current assets$66.6M$44.1M$26.9M$26.7M$22.4M
Property, plant and equipment, net$0.00$0.00$0.00$0.00$0.00
Goodwill and intangible assets$0.00$0.00$0.00$0.00$0.00
Long-term investments$2.79M$0.00$0.00$0.00$0.00
Total non-current assets$3.5M$820K$10K$210K$30K
Total assets$70.1M$45M$26.9M$26.9M$22.4M
Accounts payable$4.63M$3.24M$3.78M$2.39M$780K
Short-term debt$0.00$0.00$20K$0.00$0.00
Deferred revenue$250K$0.00$0.00$0.00$0.00
Total current liabilities$10.5M$6.92M$7.55M$4.61M$1.65M
Long-term debt$0.00$19.3M$30.9M$24.9M$4.99M
Deferred revenue, non-current$24.6M$0.00$0.00$0.00$0.00
Total non-current liabilities$24.5M$43.9M$30.9M$24.9M$4.99M
Capital lease obligations$0.00$0.00$20K$0.00$0.00
Total liabilities$35M$50.8M$38.5M$29.5M$6.64M
Common stock$189.6M$145.6M$144.3M$142.6M$140.8M
Retained earnings-$-229.36M-$-219.68M-$-219.25M-$-203.2M-$-179.49M
Accumulated other comprehensive income (loss)$1.24M$1.24M$1.24M$1.24M$1.24M
Total equity$35.1M-$-5.87M-$-11.62M-$-2.57M$15.8M
Total investments$2.79M$0.00$0.00$0.00$0.00
Total debt$0.00$19.3M$31M$24.9M$4.99M
Net debt-$-36.72M-$-7.29M$17.7M$1.12M-$-16.11M
Cash flow statement
20252024202320222021
Net income-$-10.27M-$-440K-$-16.05M-$-23.71M-$-17.35M
Depreciation and amortization$100K$960K$290K$150K$20K
Stock-based compensation$7.03M$5.06M$5.35M$4.22M$4.01M
Change in working capital-$-15.09M-$-7.33M-$-8.17M-$-510K-$-140K
Accounts receivable-$-12.66M-$-7.87M-$-7.27M-$-1.54M$0.00
Inventory-$-1.3M$580K-$-1.58M-$-580K$0.00
Accounts payable$1.42M$0.00$0.00$0.00$0.00
Net cash provided by operating activities-$-12.47M$27M-$-17.14M-$-18.06M-$-14.22M
Investments in property, plant and equipment$0.00$0.00$0.00$0.00$0.00
Acquisitions, net$0.00$0.00$0.00$0.00$0.00
Net cash used for investing activities$0.00$0.00$0.00$0.00$0.00
Common stock issued$45M$0.00$0.00$0.00$30K
Common stock repurchased$0.00-$-180K-$-80K-$-190K$0.00
Dividends paid$0.00$0.00$0.00$0.00$0.00
Net cash used for financing activities$22.6M-$-13.62M$6.64M$20.7M$4.98M
Net change in cash$10.2M$13.4M-$-10.51M$2.67M-$-9.24M
Cash at end of period$36.8M$26.6M$13.3M$23.8M$21.1M
Operating cash flow-$-12.47M$27M-$-17.14M-$-18.06M-$-14.22M
Capital expenditure$0.00$0.00$0.00$0.00$0.00
Free cash flow-$-12.47M$27M-$-17.14M-$-18.06M-$-14.22M
USD millions

Line items

    USD millions

    Line items

      USD millions

      Line items

        About Fennec Pharmaceuticals Inc.

        Fennec Pharmaceuticals Inc. operates as a biopharmaceutical firm. Its leading investigational drug in clinical development is PEDMARK, a specialized formulation of sodium thiosulfate. This treatment is designed to shield young cancer patients from hearing damage (ototoxicity) that can be induced by platinum-based chemotherapy. The company, which was founded in 1996, previously operated under the name Adherex Technologies Inc. before officially rebranding as Fennec Pharmaceuticals Inc. in September 2014. Its corporate headquarters are situated in Research Triangle Park, North Carolina.

        CEO
        Jeffrey S. Hackman
        Employees
        35
        Beta
        1.07

        Explore

        Frequently asked questions

        What is the intrinsic value of Fennec Pharmaceuticals Inc. (FENC)?

        Fennec Pharmaceuticals Inc. (FENC) is currently strongly undervalued based on the InvestorsCraft IC model — IC value is more than 50% above the price. The exact intrinsic value is available to Pro subscribers. How the IC value is calculated.

        Is FENC undervalued?

        FENC trades at a price of $13.09 (Nov 21, 2026): strongly undervalued — IC value is more than 50% above the price.

        How is the intrinsic value calculated?

        InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.

        How often is this page updated?

        Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.

        Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.